Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program

Main Article Content

Brett King
Jennifer Soung
Christos Tziotzios
Lidia Rudnicka
Pascal Joly
Melinda Gooderham
Rodney Sinclair
Susan D. Anway
Dalia Wajsbrot
Alexandre Lejeune
Samuel H. Zwillich


ritlecitinib, alopecia areata


1. Islam N, et al. Autoimmun Rev. 2015;14:81-89.

2. King B, et al. Lancet. 2023;401:1518-1529.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>